Akay S.Özütemiz Ö.Doganavsargil B.2019-10-272019-10-2720041474-0338https://doi.org/10.1517/14740338.3.2.89https://hdl.handle.net/11454/22627UFT (Uftoral®), a blend of uracil and Tegafur, is an antitumour agent for oral administration that is presumed to maintain the concentration of 5-fluorouracil (5-FU) in tumour tissue. As a result of increased use of high-dose 5-FU-based chemotherapy for various solid tumours, complicated drug-induced colitis is more frequently observed. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in the catabolism of 5-FU and its deficiency is responsible for the severe toxicities encountered in cancer patients receiving 5-FU. The authors present the case of a patient with locally advanced temporal bone carcinoma who developed haematochezia during a course of chemotherapy with UFT. Colonoscopy of the patient showed bleeding petechia-like lesions and superficial inflammatory exudate, whilst histology revealed non-specific inflammatory changes of the colon mucosa. As the haematochezia improved with supportive treatment, neutropenia complicated the clinical picture. This patient developed life-threatening UFT toxicity without an exon-14 DPD gene mutation. 2004 © Ashley Publications Ltd.en10.1517/14740338.3.2.89info:eu-repo/semantics/closedAccessColitisDihydropyrimidine dehydrogenase (DPD) deficiencyGastrointestinal (GI) side effectsUFTArticle32899215006714Q2